Novartis' Updated ASCEMBL Study Showed Sustained Efficacy Vs Bosutinib In Chronic Myeloid Leukmia
12/12 18:39
(RTTNews) - Novartis' (NVS) Scemblix demonstrated sustained response rate in 48-week data from the Phase III ASCEMBL study in patients with chronic myeloid leukemia....